Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product
Abstract Background A growing number of clinical trials have shown that regulatory T (Treg) cell transfer may have a favorable effect on the maintenance of self-tolerance and immune homeostasis in different conditions such as graft-versus-host disease (GvHD), solid organ transplantation, type 1 diab...
Main Authors: | Cristiana Lavazza, Silvia Budelli, Elisa Montelatici, Mariele Viganò, Francesca Ulbar, Lucia Catani, Marta Giulia Cannone, Sara Savelli, Elisa Groppelli, Lorenza Lazzari, Roberto M. Lemoli, Matteo Cescon, Gaetano La Manna, Rosaria Giordano, Tiziana Montemurro |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-01-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-021-03200-x |
Similar Items
-
ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing
by: D.N. Silva, et al.
Published: (2022-12-01) -
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit
by: I. Johanna, et al.
Published: (2023-12-01) -
MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process
by: Chantal Lechanteur, et al.
Published: (2021-05-01) -
Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization
by: Daniela Celeste Profico, et al.
Published: (2022-11-01) -
Validation of the media fill method for Cytokine-Induced killer cells manufacturing process
by: Ivana Ferrero, et al.
Published: (2023-08-01)